18F-Pentixafor PET in Hematologic Malignancies

ConditionHematological Malignancies

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-80

SponsorFirst Affiliated Hospital of Zhejiang University

About this trial

The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.

Eligibility criteria

Qualifiers

Age of 18-80 years old, both sexes, with behavioral capacity;

patients with suspected or confirmed hematological malignancies;

18F-FDG PET or other imaging examinations should be performed according to the treatment plan;

For suspected patients, biopsy or needle biopsy is expected to obtain pathological results;

Disqualifiers

pregnant and lactating women;

patients with fear or radiophobia, or with mental disorder or primary affective disorder;

received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv;

received investigational drugs or devices of uncertain efficacy or safety within 1 month;

Trial design

Treatments tested in this trial

18F-Pentixafor

Treatment groups

100 Participants

are divided into 1 treatment group

Sponsors and collaborators

First Affiliated Hospital of Zhejiang University

Lead sponsor

Source ClinicalTrials.gov